Elicera Therapeutics AB
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing EL… Read more
Elicera Therapeutics AB (ELIC) - Net Assets
Latest net assets as of September 2025: Skr30.33 Million SEK
Based on the latest financial reports, Elicera Therapeutics AB (ELIC) has net assets worth Skr30.33 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr37.30 Million) and total liabilities (Skr6.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr30.33 Million |
| % of Total Assets | 81.31% |
| Annual Growth Rate | 48.78% |
| 5-Year Change | 102.91% |
| 10-Year Change | 2437.72% |
| Growth Volatility | 473.31 |
Elicera Therapeutics AB - Net Assets Trend (2014–2024)
This chart illustrates how Elicera Therapeutics AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Elicera Therapeutics AB (2014–2024)
The table below shows the annual net assets of Elicera Therapeutics AB from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr20.77 Million | +26.64% |
| 2023-12-31 | Skr16.40 Million | -49.99% |
| 2022-12-31 | Skr32.80 Million | -37.21% |
| 2021-12-31 | Skr52.24 Million | +410.33% |
| 2020-12-31 | Skr10.24 Million | +1566.84% |
| 2019-12-31 | Skr614.10K | -23.73% |
| 2018-12-31 | Skr805.16K | -0.44% |
| 2017-12-31 | Skr808.69K | -0.61% |
| 2016-12-31 | Skr813.65K | -0.59% |
| 2015-12-31 | Skr818.47K | +109.53% |
| 2014-12-31 | Skr390.63K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Elicera Therapeutics AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19865.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr1.47 Million | 7.10% |
| Other Components | Skr86.62 Million | 417.05% |
| Total Equity | Skr20.77 Million | 100.00% |
Elicera Therapeutics AB Competitors by Market Cap
The table below lists competitors of Elicera Therapeutics AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DJ Mediaprint & Logistics Limited
NSE:DJML
|
$9.78 Million |
|
Filatex Fashions Limited
NSE:FILATFASH
|
$9.78 Million |
|
Globe International Ltd
AU:GLB
|
$9.78 Million |
|
Wing Yip Food Holdings Group Limited American Depositary Shares
NASDAQ:WYHG
|
$9.78 Million |
|
477380
KQ:477380
|
$9.78 Million |
|
RE Royalties Ltd
OTCQX:RROYF
|
$9.78 Million |
|
Investeringsselskabet Luxor A/S
CO:LUXOR-B
|
$9.78 Million |
|
Selangor Dredging Bhd
KLSE:2224
|
$9.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Elicera Therapeutics AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 16,401,458 to 20,770,437, a change of 4,368,979 (26.6%).
- Net loss of 16,110,000 reduced equity.
- New share issuances of 20,479,306 increased equity.
- Other comprehensive income decreased equity by 5,000,000.
- Other factors increased equity by 4,999,673.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-16.11 Million | -77.56% |
| Share Issuances | Skr20.48 Million | +98.6% |
| Other Comprehensive Income | Skr-5.00 Million | -24.07% |
| Other Changes | Skr5.00 Million | +24.07% |
| Total Change | Skr- | 26.64% |
Book Value vs Market Value Analysis
This analysis compares Elicera Therapeutics AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.06x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 163.25x to 8.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr0.03 | Skr5.30 | x |
| 2015-12-31 | Skr0.07 | Skr5.30 | x |
| 2016-12-31 | Skr0.07 | Skr5.30 | x |
| 2017-12-31 | Skr0.07 | Skr5.30 | x |
| 2018-12-31 | Skr0.07 | Skr5.30 | x |
| 2019-12-31 | Skr0.05 | Skr5.30 | x |
| 2020-12-31 | Skr0.55 | Skr5.30 | x |
| 2021-12-31 | Skr3.28 | Skr5.30 | x |
| 2022-12-31 | Skr1.66 | Skr5.30 | x |
| 2023-12-31 | Skr0.83 | Skr5.30 | x |
| 2024-12-31 | Skr0.66 | Skr5.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Elicera Therapeutics AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -77.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -226.01%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.33x
- Recent ROE (-77.56%) is below the historical average (-13.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 116.27% | 0.00% | 0.00x | 2.53x | Skr415.11K |
| 2015 | 52.27% | 0.00% | 0.00x | 1.45x | Skr345.99K |
| 2016 | -0.59% | 0.00% | 0.00x | 1.15x | Skr-86.19K |
| 2017 | -0.61% | 0.00% | 0.00x | 1.00x | Skr-85.83K |
| 2018 | -0.44% | 0.00% | 0.00x | 1.00x | Skr-84.04K |
| 2019 | -30.59% | 0.00% | 0.00x | 1.01x | Skr-249.29K |
| 2020 | -27.58% | 0.00% | 0.00x | 1.23x | Skr-3.85 Million |
| 2021 | -25.12% | -2235169.17% | 0.00x | 1.05x | Skr-18.34 Million |
| 2022 | -59.50% | -1524.61% | 0.03x | 1.41x | Skr-22.79 Million |
| 2023 | -99.98% | -146.02% | 0.37x | 1.84x | Skr-18.04 Million |
| 2024 | -77.56% | -226.01% | 0.26x | 1.33x | Skr-18.19 Million |
Industry Comparison
This section compares Elicera Therapeutics AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Elicera Therapeutics AB (ELIC) | Skr30.33 Million | 116.27% | 0.23x | $9.78 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |